Drug intelligence / Profile preview

NTX-253

Development stage: Phase 1
Lead developer: Neurosterix
Modality: Small Molecules
Administration: Oral

Overview

NTX-253 is a positive allosteric modulator (PAM) targeting the M4 muscarinic acetylcholine receptor. It is being advanced for the treatment of schizophrenia. The drug was part of Addex Therapeutics' portfolio of allosteric modulator programs, which were spun out into a new company, Neurosterix, in April 2024. Neurosterix is now responsible for advancing NTX-253.

Targets

CHRM4 (M4)

Beyond the preview

Go deeper on NTX-253.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTX-253.

Explore the full profile